Nanexa AB today announced that the company has signed an additional so-called Material Transfer and Feasibility Study Agreement with one of the company’s existing customers, for evaluation of the PharmaShell® technology with a specific biological drug substance.
Nanexa has previously collaborated with this big pharmaceutical company around the possibilities of combining the PharmaShell technology with different drug substances. This is further step in that collaboration.
“It is very exciting to continue our collaboration, which with this agreement enters into a new phase. We look forward to starting the work shortly and that this evaluation can generate results that can be the basis for a more extensive and long-term development agreement,” says David Westberg, CEO of Nanexa.
The agreement regulates, among other things, details of what shall be investigated, clarification regarding patent rights and a smaller determined fee to Nanexa for this evaluation.
This information was distributed by MFN https://www.mfn.se/